Investigating a metabolite's role in asthma
Lysophosphatidylglycerol in Asthma Pathogenesis
This study is looking at how a substance called lysophosphatidylglycerol (LPG) might be connected to asthma symptoms and treatment in people with asthma compared to healthy individuals.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Peking University Third Hospital Academic / other |
| Locations | 1 site (Beijing, None Selected) |
| Trial ID | NCT06327516 on ClinicalTrials.gov |
What this trial studies
This observational study examines the relationship between lysophosphatidylglycerol (LPG) and asthma by analyzing metabolomics data from asthma patients and healthy controls. It explores how LPG correlates with various clinical features of asthma, such as exacerbations, control levels, treatment steps, lung function, and inflammatory markers. Additionally, in vitro tests will be conducted to understand LPG's mechanism in influencing Treg function and its role in asthma inflammation.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals with a clinical diagnosis of asthma.
Not a fit: Patients with conditions such as chronic obstructive pulmonary disease, severe cardiovascular disease, or those who are pregnant may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new insights into asthma pathogenesis and potential biomarkers for better management of the condition.
How similar studies have performed: While this study explores a novel approach, previous studies have indicated the importance of metabolites in asthma, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. clinical diagnosis of asthma. Exclusion Criteria: 1. Combined with chronic obstructive pulmonary disease, bronchiectasis, pneumonia, obstructive sleep apnea hypopnea syndrome, malignant tumor 2. Combined with acute and chronic respiratory failure 3. Combined with severe cardiovascular disease 4. Pregnant woman.
Where this trial is running
Beijing, None Selected
- Peking university third hospital — Beijing, None Selected, China (Recruiting)
Study contacts
- Principal investigator: Chun Chang — Peking University Third Hospital
- Study coordinator: Chun Chang
- Email: doudou1977bysy@sina.com
- Phone: 15810075362
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.